Trial reportBioscience reports2017
The relationship between circulating irisin levels and tissues AGE accumulation in type 2 diabetes patients.
Trial report in Bioscience reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Evaluation of serum irisin level and severity of erectile dysfunction in diabetic males: a cross sectional prospective study.Diabetology & metabolic syndrome · 2024Article
- Swimming alleviates myocardial fibrosis of type II diabetic rats through activating miR-34a-mediated SIRT1/PGC-1α/FNDC5 signal pathway.PloS one · 2024Article
- Serum Irisin Levels are Inversely Correlated with Acute Ischaemic Stroke Incidence: Implications for Early Diagnosis in Southern China.International journal of general medicine · 2024Article
- Association between Serum Irisin and Leptin Levels and Risk of Depressive Symptoms in the Diabetic Elderly Population.Journal of clinical medicine · 2023Article
- A Role for Advanced Glycation End Products in Molecular Ageing.International journal of molecular sciences · 2023Review
- Relationship of irisin expression with metabolic alterations and cardiovascular risk in type 2 diabetes mellitus: a preliminary study.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Is skin autofluorescence a novel non-invasive marker in diabetes? A systematic review and meta-analysis of case-control studies.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Review
- Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.Nutrients · 2022Review
- Endogenous Protective Factors and Potential Therapeutic Agents for Diabetes-Associated Atherosclerosis.Frontiers in endocrinology · 2022Review
- Clinical Significance of Non-invasive Skin Autofluorescence Measurement in Patients with Diabetes: A Systematic Review and Meta-analysis.EClinicalMedicine · 2021Article
- Adherence to Mediterranean diet and advanced glycation endproducts in patients with diabetes.World journal of diabetes · 2021Article
- Advanced Glycation End Products: New Clinical and Molecular Perspectives.International journal of environmental research and public health · 2021Review
- Irisin plays an important role in the outcomes of newly diagnosed prediabetes in adults in Guiyang, China.Journal of diabetes investigation · 2021Article
- The Potential Role of Irisin in Vascular Function and Atherosclerosis: A Review.International journal of molecular sciences · 2020Review
- Recent Advances and the Potential for Clinical Use of Autofluorescence Detection of Extra-Ophthalmic Tissues.Molecules (Basel, Switzerland) · 2020Review
- Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health.Journal of clinical medicine · 2020Article
- Observational
- Association of Circulating Irisin Levels with Adiposity and Glucose Metabolic Profiles in a Middle-Aged Chinese Population: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Irisin and markers of metabolic derangement in non-diabetic Caucasian subjects with stage I-II obesity during early aging.PloS one · 2020Article
- Irisin in metabolic diseases.Endocrine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced glycation end-products (AGEs), measured by skin autofluorescence (AF), are a factor in the development or worsening of many degenerative diseases, such as diabetes and atherosclerosis. Irisin levels have been associated with diabetes, endothelial dysfunction and atherosclerosis. The objective of the present study was to investigate whether circulating irisin levels are correlated with skin AF values in type 2 diabetes patients. A total of 362 Chinese type 2 diabetic patients and 100 age- and sex-matched healthy controls were recruited in the present study. Clinical characteristics, blood biochemistry and circulating irisin levels were measured. Skin AF was measured using an AGE reader. Circulating irisin levels were significantly lower, while skin AF values were increased in type 2 diabetes compared with controls (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.